Cartesian’s headquarters are located at 7495 New Horizon Way, Frederick, MD 21703.
Cartesian is incorporated in Delaware.
Cartesian’s common stock is traded on the Nasdaq Global Market under the ticker symbol RNAC, and its CUSIP number is 816212 302.
Cartesian (formerly known as Selecta Biosciences, Inc.) began trading under the ticker symbol RNAC on November 14, 2023, following the closing of its merger with the private company then known as Cartesian Therapeutics, Inc. Prior to the merger, the company traded under the ticker symbol SELB.
Cartesian does not currently offer a dividend reinvestment program, and does not expect to declare or pay dividends on its common stock in the foreseeable future.
Cartesian’s fiscal year ends on December 31st.
Cartesian’s transfer agent is Equiniti Trust Company, LLC and communications to Equiniti should be directed to:
Equiniti Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
800-937-5449
• Legal Counsel: Covington & Burling LLP
Brian K. Rosenzweig
The New York Times Building, 620 Eighth Avenue
New York, NY 10018-1405
+1 212-841-1108
• Independent Auditor: Ernst & Young LLP
200 Clarendon Street
Boston, MA 02116
617-266-2000
Cartesian’s filings with the SEC can be accessed in the Financial Information section of our Investors webpage and at the SEC’s website at www.sec.gov.
Please click here to be directed to the email alerts page.
For media, investor, and other inquiries, please send an email to cartesian@argotpartners.com.
If you wish to report any compliance concerns regarding Cartesian or any of its employees or contractors, you may do so confidentially and anonymously, where permitted by local law, by using the Confidential and Anonymous Financial Concern Hotline that is available 24 hours a day, 7 days a week by telephone at 844-421-3583, by email to RNAC@openboard.info, or on the Internet at http://www.openboard.info/RNAC/.